Showing results (171-180 of 288) with videos related to

Sort By:
Pageof 29
The Lancet. Respiratory Medicine|January 26, 2023
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyAndrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, et al.
Journal of Leukocyte Biology|March 8, 2024
Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunitiesPaneez Khoury, Florence Roufosse, Fei Li Kuang, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 2, 2024
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION studyChristopher E Brightling, Marco Caminati, Jean-Pierre Llanos, et al.
The Journal of Rheumatology|June 9, 2005
Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspectiveLeslie R Harrold, Susan E Andrade, Alan S Go, et al.
Pharmacoepidemiology and Drug Safety|December 29, 2006
Asthma drug use and the development of Churg-Strauss syndrome (CSS)Leslie R Harrold, M Kay Patterson, Susan E Andrade, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 22, 2025
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With PolyangiitisParameswaran K Nair, Bernhard Hellmich, Arnaud Bourdin, et al.
The Lancet. Respiratory Medicine|May 18, 2026
Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trialMichael E Wechsler, Christopher E Brightling, Guy Brusselle, et al.
The New England Journal of Medicine|February 23, 2024
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with PolyangiitisMichael E Wechsler, Parameswaran Nair, Benjamin Terrier, et al.
American Journal of Respiratory and Critical Care Medicine|June 13, 2015
Impact of Age and Sex on Response to Asthma TherapyRyan M Dunn, Erik Lehman, Vernon M Chinchilli, et al.
The European Respiratory Journal|September 26, 2024
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studiesMichael E Wechsler, Guy Brusselle, J Christian Virchow, et al.
Pageof 29